Villanueva-Badenas Estela, Donato M Teresa, Tolosa Laia
Unidad de Hepatología Experimental, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
Departamento de Bioquímica y Biología Molecular, Facultad de Medicina y Odontología, Universidad de Valencia, 46010 Valencia, Spain.
Antioxidants (Basel). 2023 Jun 21;12(7):1315. doi: 10.3390/antiox12071315.
Hepatotoxicity or drug-induced liver injury (DILI) is a major safety issue in drug development as a primary reason for drug failure in clinical trials and the main cause for post-marketing regulatory measures like drug withdrawal. Idiosyncratic DILI (iDILI) is a patient-specific, multifactorial, and multicellular process that cannot be recapitulated in current in vitro models; thus, our major goal is to develop and fully characterize a co-culture system and to evaluate its suitability for predicting iDILI. For this purpose, we used human hepatoma HepG2 cells and macrophages differentiated from a monocyte cell line (THP-1) and established the appropriate co-culture conditions for mimicking an inflammatory environment. Then, mono-cultures and co-cultures were treated with model iDILI compounds (trovafloxacin, troglitazone) and their parent non-iDILI compounds (levofloxacin, rosiglitazone), and the effects on viability and the mechanisms implicated (i.e., oxidative stress induction) were analyzed. Our results show that co-culture systems including hepatocytes (HepG2) and other cell types (THP-1-derived macrophages) help to enhance the mechanistic understanding of iDILI, providing better hepatotoxicity predictions.
肝毒性或药物性肝损伤(DILI)是药物研发中的一个主要安全问题,是临床试验中药物失败的主要原因,也是撤药等上市后监管措施的主要原因。特异质性DILI(iDILI)是一个特定于患者的、多因素的和多细胞的过程,目前的体外模型无法重现;因此,我们的主要目标是开发并全面表征一种共培养系统,并评估其预测iDILI的适用性。为此,我们使用了人肝癌HepG2细胞和从单核细胞系(THP-1)分化而来的巨噬细胞,并建立了模拟炎症环境的合适共培养条件。然后,用iDILI模型化合物(曲伐沙星、曲格列酮)及其非iDILI母体化合物(左氧氟沙星、罗格列酮)处理单培养物和共培养物,并分析对细胞活力的影响以及涉及的机制(即氧化应激诱导)。我们的结果表明,包括肝细胞(HepG2)和其他细胞类型(THP-1来源的巨噬细胞)的共培养系统有助于增强对iDILI的机制理解,提供更好的肝毒性预测。